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Summary
Background Chronic kidney disease is an important cause of global mortality and morbidity. Data for epidemiological 
features of chronic kidney disease and its risk factors are limited for low-income and middle-income countries. The 
International Society of Nephrology’s Kidney Disease Data Center (ISN-KDDC) aimed to assess the prevalence and 
awareness of chronic kidney disease and its risk factors, and to investigate the risk of cardiovascular disease, in countries 
of low and middle income. 
Methods We did a cross-sectional study in 12 countries from six world regions: Bangladesh, Bolivia, Bosnia and 
Herzegovina, China, Egypt, Georgia, India, Iran, Moldova, Mongolia, Nepal, and Nigeria. We analysed data from 
screening programmes in these countries, matching eight general and four high-risk population cohorts collected in 
the ISN-KDDC database. High-risk cohorts were individuals at risk of or with a diagnosis of either chronic kidney 
disease, hypertension, diabetes, or cardiovascular disease. Participants completed a self-report questionnaire, had 
their blood pressure measured, and blood and urine samples taken. We deﬁ ned chronic kidney disease according to 
modiﬁ ed KDIGO (Kidney Disease: Improving Global Outcomes) criteria; risk of cardiovascular disease development 
was estimated with the Framingham risk score.
Findings 75 058 individuals were included in the study. The prevalence of chronic kidney disease was 14·3% (95% CI 
14·0–14·5) in general populations and 36·1% (34·7–37·6) in high-risk populations. Overall awareness of chronic 
kidney disease was low, with 409 (6%) of 6631 individuals in general populations and 150 (10%) of 1524 participants 
from high-risk populations aware they had chronic kidney disease. Moreover, in the general population, 
5600 (44%) of 12 751 individuals with hypertension did not know they had the disorder, and 973 (31%) of 3130 people 
with diabetes were unaware they had that disease. The number of participants at high risk of cardiovascular disease, 
according to the Framingham risk score, was underestimated compared with KDIGO guidelines. For example, all 
individuals with chronic kidney disease should be considered at high risk of cardiovascular disease, but the 
Framingham risk score detects only 23% in the general population, and only 38% in high-risk cohorts.
Interpretation Prevalence of chronic kidney disease was high in general and high-risk populations from countries of 
low and middle income. Moreover, awareness of chronic kidney disease and other non-communicable diseases was 
low, and a substantial number of individuals who knew they were ill did not receive treatment. Prospective programmes 
with repeat testing are needed to conﬁ rm the diagnosis of chronic kidney disease and its risk factors. Furthermore, in 
general, health-care workforces in countries of low and middle income need strengthening.
Funding International Society of Nephrology.
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Introduction
Chronic kidney disease is an important cause of global 
morbidity and mortality.1,2 In the 2013 Global Burden of 
Disease study, 956 200 people were estimated to have 
died from chronic kidney disease, a 134% increase from 
1990, one of the largest rises among the top causes of 
death.1 Furthermore, even in the early stages of chronic 
kidney disease, the risk of fatal and non-fatal 
cardiovascular events attributable directly to renal disease 
rises substantially.3 Thus, kidney disease should be a 
global public health priority, particularly because, 
worldwide, more than 1·4 million individuals with 
end-stage renal disease are estimated to receive renal 
replacement therapy with dialysis or transplantation, 
with 8% annual growth.4 A steep increase in cases of 
hypertension, diabetes, and other diseases that are risk 
factors for chronic kidney disease is also driving growth 
in prevalence of chronic kidney disease, putting 
enormous pressure on health-care resources.5
High-quality screening programmes in high-income 
countries, including the USA,6 Norway,7 the Netherlands,8 
and Australia,9 have shown the prevalence of chronic 
kidney disease in the general adult population is 10–13%. 
However, for many low-income and middle-income 
countries and regions, data for epidemiological features 
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of chronic kidney disease are scarce or even missing10 
because of an absence of resources, inadequate data 
collection methods, and low awareness of the disorder. 
Moreover, in these diﬀ erent settings, the primary causes 
of chronic kidney disease vary, and kidney disease might 
not be contained entirely within the envelope of diabetes 
and hypertension. Indeed, in developing countries, up to 
40% of individuals whose chronic kidney disease is 
identiﬁ ed in screening programmes do not have diabetes 
or cardiovascular disease; other risk factors such as HIV,11 
tuberculosis, and exposure to toxins12 can cause chronic 
kidney disease, or the cause could remain unknown.13 
Therefore, careful assessment of epidemiological features 
of chronic kidney disease is needed, particularly for 
people living in countries of low and middle income who 
cannot aﬀ ord the high costs of renal replacement therapy.5
In 2005, the International Society of Nephrology (ISN) 
established programmes to build global capacity to screen 
populations to detect chronic kidney disease and its risk 
factors early, and for patients’ management and follow-
up.14 To support data collection and analysis, ISN also 
funded the establishment of a global database, the Kidney 
Disease Data Center (KDDC), which provided the unique 
opportunity to gather information using a simple and 
uniform template. In the ISN-KDDC cross-sectional 
study, we aimed to estimate the prevalence of chronic 
kidney disease according to the latest KDIGO (Kidney 
Disease: Improving Global Outcomes) guidelines,3 to 
investigate awareness of chronic kidney disease and its 
major risk factors, to assess risk factors associated with 
chronic kidney disease, and to calculate cardiovascular 
risk for screened populations.
Methods
Study population
We identiﬁ ed adult cohorts in the KDDC database 
from 12 low-income and middle-income countries: 
Bangladesh, Bolivia, Bosnia and Herzegovina, China, 
Egypt, Georgia, India, Iran, Moldova, Mongolia, Nepal, 
and Nigeria. Almost all cohorts, with the exception of the 
Iranian cohort, included participants from the ISN 
programme on Detection and Management of 
Chronic Kidney Disease, Hypertension, Diabetes and 
Cardiovascular Disease in Developing Countries 
(KHDC).14 KHDC guidelines provide a template for 
setting up early detection and intervention programmes 
Research in context
Evidence before this study
Several systematic reviews have been done to assess prevalence 
of chronic kidney disease, and in the 2013 Global Burden of 
Disease Study, mortality and morbidity from chronic kidney 
disease was estimated. To retrieve the most representative 
examples of screening programmes done in randomly selected 
populations or community settings, particularly low-income 
and middle-income countries, we did a non-systematic search 
of PubMed with the keywords “chronic kidney disease 
(community OR random) screening” and “chronic kidney 
disease awareness”, and we searched manually through the 
recent content of relevant journals, up to July, 2015. In 2013, 
956 200 deaths globally were attributed directly to chronic 
kidney disease, one of the highest increases in the past 
two decades. In several (mainly developed) countries, screening 
programmes detected a high prevalence of chronic kidney 
disease and low awareness. Criteria for chronic kidney disease 
and its components varied substantially between some of these 
screening programmes, and most were done with diﬀ erent 
methods, developed by local researchers. The latest KDIGO 
(Kidney Disease: Improving Global Outcomes) guidelines 
standardised the classiﬁ cation and prognosis of chronic kidney 
disease based on glomerular ﬁ ltration rate (GFR) and 
albuminuria categories.
Added value of this study
Our cross-sectional data were obtained from screening 
programmes done on behalf of the International Society of 
Nephrology (ISN), across diﬀ erent populations from 
low-income and middle-income countries, but using a uniform 
process and deﬁ nition of chronic kidney disease. Decreased 
estimated GFR (eGFR) and increased albuminuria, and the 
resulting positive screening for prevalence of chronic kidney 
disease, are common in the general population of countries of 
low and middle income. Our applied screening method allowed 
estimation of low awareness, not only of chronic kidney disease 
but also of hypertension and diabetes. Moreover, a substantial 
proportion of individuals with known diseases did not take 
drugs, indicating poor access to basic treatment. Our data 
conﬁ rmed an association between a positive screening test for 
chronic kidney disease and hypertension, diabetes, obesity, and 
high amounts in serum of cholesterol. We noted an incremental 
increase and cumulative eﬀ ect of reduced eGFR and increased 
albuminuria on the Framingham risk score of developing 
cardiovascular disease within the next 10 years, but this risk was 
substantially underestimated in almost all patients with chronic 
kidney disease.
Implications of all the available evidence
Current recommendations in developed countries do not 
encourage screening for chronic kidney disease in the general 
population. However, in countries of low and middle income, 
we advocate screening programmes with conﬁ rmatory testing 
as a unique method for detecting chronic kidney disease and 
other non-communicable diseases, with subsequent prevention, 
follow-up, and treatment. Further cost-eﬀ ectiveness analyses 
should quantify the beneﬁ t of such programmes for limitation 
of morbidity and mortality related to renal and cardiovascular 
complications. The epidemiology of chronic kidney disease has 
to be studied worldwide, and the ready-to-use method 
developed by ISN could help to achieve this important goal. 
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in developing countries based on speciﬁ c needs, 
organisation facilities, and economic imperatives of each 
country. Volunteer bias was not handled in the 
KHDC-based screenings.
General population cohorts in the KDDC database 
(from KHDC-based programmes) were from eastern 
Asia (China,15 Mongolia15), southern Asia (India,16 
Nepal15), Africa (Nigeria), eastern Europe (Moldova17), and 
Latin America (Bolivia18). Data from a non-KHDC 
screening programme were available for a large-scale, 
general population, cross-sectional survey in Tehran, 
Iran.19 High-risk population cohorts, deﬁ ned as 
individuals at risk of or with a diagnosis of chronic 
kidney disease, hypertension, diabetes, or cardiovascular 
disease, were from southern Asia (Bangladesh18), the 
Middle East (the EGIPT-CKD programme in Damanhour, 
Egypt20), and eastern Europe (Bosnia and Herzegovina, 
Georgia18). In Bangladesh, high-risk individuals were 
identiﬁ ed at the ﬁ rst screening interview; in Egypt, those 
at high risk were ﬁ rst-degree relatives of patients treated 
for chronic kidney disease with known microalbuminuria; 
in Bosnia and Herzegovina, high-risk individuals were 
inhabitants of Balkan endemic nephropathy areas, 
refugee camps, or gypsy communities; and in Georgia, 
those at high risk were people at risk of non-
communicable diseases diagnosed in university 
hospitals.
We judged participants eligible for our study if they 
were aged 18 years or older and had complete data for 
calculation of estimated glomerular ﬁ ltration rate (eGFR) 
and for assessment of albuminuria. All KHDC-based 
programmes included in this study, and the one from 
Iran, have been approved by the ethics committees of 
local hospitals (or equivalent when available), and written 
or oral consent was obtained from participants.
Procedures
Questionnaires based on the KHDC template comprise 
self-reported information on sociodemographic factors 
(date of birth, sex, marital status, ethnic origin, level of 
education, and work), lifestyle (smoking, alcohol 
consumption, physical activity, and fruit and vegetable 
consumption), and medical history (chronic kidney 
disease, hypertension, diabetes, and cardiovascular 
disease), and we included these data when available. 
We coded data from the non-KHDC programme19 in the 
same format as the KHDC template then imported it 
into the ISN-KDDC study database. We categorised 
ethnic origin as eastern or southern Asian, black African, 
white, and other—a group that included Hispanic and 
indigenous together.
For more than 85% of participants, measurement of 
serum creatinine was possible, in addition to dipstick 
testing for albuminuria or proteinuria; furthermore, for a 
smaller subset (26%), the albumin-to-creatinine ratio 
(ACR) or protein-to-creatinine ratio was also available. 
We calculated eGFR (in mL/min per 1·73 m²) with the 
CKD-EPI equation,21 based on serum creatinine, age, 
sex, and a two-level racial variable (black vs other). 
We deﬁ ned eGFR categories as: G1, normal or high 
(≥90 mL/min per 1·73 m²); G2, mildly decreased 
(60–89 mL/min per 1·73 m²); G3a, mildly to moderately 
decreased (45–59 mL/min per 1·73 m²); G3b, moderately 
to severely decreased (30–44 mL/min per 1·73 m²); G4, 
severely decreased (15–29 mL/min per 1·73 m²) and G5, 
kidney failure (<15 mL/min per 1·73 m²).3 We assessed 
albuminuria as ACR approximate equivalent,3,22 using an 
algorithm that relies on ACR, protein-to-creatinine ratio, 
and protein dipstick, strictly in this order. We deﬁ ned 
albuminuria categories as: A1 (normal to mildly 
increased) for ACR less than 30 mg/g, protein-to-
Figure 1: Flow diagram of cohorts included in the ISN-KDDC study
eGFR=estimated glomerular ﬁ ltration rate. KDDC=Kidney Disease Data Center. 
KHDC=International Society of Nephrology programme on Detection and 
Management of Chronic Kidney Disease, Hypertension, Diabetes and 
Cardiovascular Disease in Developing Countries.
12 adult cohorts identified in
the KDDC database
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Eastern Asia
•  China (n=10 091)15
•  Mongolia (n=1082)15
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•  Nepal (n=21 809)15,18
Africa
•  Nigeria (n=1939)
Eastern Europe
•  Moldova (n=2145)17
Latin America
•  Bolivia (n=3469)18
High-risk population cohorts
Southern Asia
•  Bangladesh (n=11 016)18
Middle East
•  Egypt (n=417)20
Eastern Europe
•  Bosnia and Herzegovina (n=808)
•  Georgia (n=1623)18
Non-KHDC programmes
General population cohorts
Middle East
•  Iran (n=31 967)19
89 567 total records
75 703 general population cohorts
13 864 high-risk population cohorts
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or missing data for eGFR 
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creatinine ratio less than 150 mg/g, or protein dipstick – 
to +/–; A2 (moderately increased) for ACR 30 mg/g to 
less than 300 mg/g, protein-to-creatinine ratio 150 mg/g 
to less than 500 mg/g, or protein dipstick 1+; and A3 
(severely increased) for ACR 300 mg/g or higher, protein-
to-creatinine ratio 500 mg/g or higher, or protein dipstick 
2+ or higher. We deﬁ ned chronic kidney disease 
according to KDIGO guidelines3 as either decreased 
eGFR (<60 mL/min per 1·73 m²) or albuminuria (ACR 
approximate equivalent >30 mg/g).
In subsets of participants who self-reported 
information about chronic kidney disease, hypertension, 
diabetes, and related treatments, we calculated the 
prevalence of awareness of the disease or treatment by 
dividing the number of people who self-reported the 
disease or treatment by the number who were classiﬁ ed 
as having the disease or taking the treatment, according 
to objective criteria. We deﬁ ned hypertension as: systolic 
blood pressure of 140 mm Hg or higher, diastolic blood 
pressure of 90 mm Hg or higher, or both;23 use of 
antihypertensive drugs; or both of these. We deﬁ ned 
diabetes as: fasting glucose of 7·0 mmol/L or higher; 
glycated haemoglobin of 6·5% or higher (48 mmol/mol); 
or use of antidiabetes drugs. We deﬁ ned obesity as a 
body-mass index (BMI) of 27·5 kg/m² or higher for 
Asian populations24 and 30 kg/m² or higher for all other 
populations.25 We deﬁ ned hypercholesterolaemia as total 
cholesterol of 6·0 mmol/L or higher in individuals 
without previous cardiovascular disease or 5·0 mmol/L 
or higher in those with previous cardiovascular disease.22
For individuals who did not self-report cardiovascular 
disease (95%), we assessed the risk of developing this 
disorder within the next 10 years with the Framingham 
risk score,26 a model that has achieved good results 
nationally and internationally.27,28 Cholesterol could be 
measured in a small subset of participants (53%); thus, 
we chose the simpler risk prediction model based on non-
laboratory predictors, incorporating BMI instead of total 
and HDL cholesterol.26 This model assumes sex-speciﬁ c 
coeﬃ  cients for the probability of the individual developing 
cardiovascular disease within the next 10 years, based on 
age, diabetes, and smoking status, treated or untreated 
Total (n=75 058) General population (n=70 774) High-risk population (n=4284)
Age (years) 44·5 (13·8) 44·2 (13·5) 49·7 (16·0)
Men 46 664 (62%) 45 041 (64%) 1623 (38%)
Women 28 394 (38%) 25 733 (36%) 2661 (62%)
Ethnic origin
Eastern Asian 8168 (11%) 8168 (12%) 0 (0%)
Southern Asian 25 757 (34%) 24 244 (34%) 1513 (35%)
Black African 1934 (3%) 1934 (3%) 0 (0%)
White 35 793 (48%) 33 022 (47%) 2771 (65%)
Other 3406 (5%) 3406 (5%) 0 (0%)
Active worker 17 797/33 803 (53%) 15 590/30 072 (52%) 2207/3731 (59%)
Educated to high school or above 11 637/34 729 (34%) 10 724/30 972 (35%) 913/3757 (24%)
Smoker 8634/37 804 (23%) 7416/33 908 (22%) 1318/3896 (34%)
Awareness*
Chronic kidney disease 559/8155 (7%) 409/6631 (6%) 150/1524 (10%)
Hypertension 9153/15 461 (59%) 7151/12 751 (56%) 2002/2710 (74%)
Diabetes 2745/3868 (71%) 2157/3130 (69%) 588/738 (80%)
Self-reported cardiovascular disease† 1780/37 841 (5%) 1342/33 690 (4%) 438/4151 (11%)
Body-mass index (kg/m2) 24·9 (4·5) 24·8 (4·4) 26·0 (6·1)
Systolic blood pressure (mm Hg) 121 (18) 120 (17) 135 (24)
Diastolic blood pressure (mm Hg) 78 (11) 78 (11) 84 (12)
Mean arterial pressure (mm Hg) 93 (12) 92 (12) 101 (15)
Fasting blood glucose (mmol/L) 5·1 (2·0), n=38 630 5·1 (2·0), n=34 943 5·6 (2·3), n=3687
Total cholesterol (mmol/L) 4·7 (1·1), n=59 425 4·7 (1·1), n=58 721 5·1 (1·2), n=704
Triglycerides (mmol/L) 1·6 (1·1–2·1), n=57 467 1·6 (1·1–2·1), n=56 764 1·3 (0·9–1·9), n=703
Serum creatinine (μmol/L) 85·7 (27·4) 86·6 (27·4) 92·8 (61·0)
eGFR (mL/min per 1·73 m2) 88·4 (21·4) 88·0 (21·2) 81·6 (31·9)
Urine albumin-to-creatinine ratio (mg/g) 7·7 (0·7–19·8), n=19 634 7·1 (0·7–19·3), n=19 052 21·4 (10·1–77·0), n=582
Urine proteins dipstick ≥1+ 2025/69 872 (3%) 1661/67 514 (2%) 364/2358 (15%)
Data are mean (SD), number of participants (%), or median (IQR), unless stated otherwise. Variable denominators indicate the number of available records. eGFR=estimated 
glomerular ﬁ ltration rate. *Calculated only for patients with disease diagnosis by objective criteria. †Includes any of the following: stroke, ischaemic heart disease, or 
peripheral artery disease.
Table 1: Characteristics of participants 
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hypertension, and BMI. We stratiﬁ ed the 10-year risk of 
developing cardiovascular disease into three categories, 
low (<10%), medium (10% to <20%), and high (≥20%),28 
irrespective of existing chronic kidney disease or a related 
risk factors disorder.
Statistical analysis
We did not impute missing values into the study database 
or do case-wise deletion; therefore, the total number of 
participants diﬀ ered by variable of interest. We tabulated 
descriptive statistics by count or percentage and used 
95% CIs for categorical variables and either mean and SD 
or median and IQR (when appropriate), for continuous 
data. To investigate the possible association between risk 
factors and chronic kidney disease in the general 
population cohorts, we used univariable and multiple 
logistic regression. The predictors we included in the 
multiple logistic regression models were dichotomous 
risk factors for kidney damage (hypertension, diabetes, 
obesity, hypercholesterolaemia), cohort, and their 
interaction. We further adjusted the above models by age 
(change by 10 years) and sex. We judged p less than 0·05 
signiﬁ cant. We did all statistical analyses with R.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data in 
the study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Figure 1 shows the process for selection of cohorts for the 
ISN-KDDC study. After exclusion of non-eligible records, 
75 058 participants were included; 70 774 (94%) study 
participants were from seven general population cohorts 
and one healthy population cohort (Iran19) and the 
remaining 4284 (6%) individuals were from four high-risk 
population cohorts. Sociodemographic and clinical 
characteristics of the participants are listed in table 1. Mean 
age was 44·5 years (SD 13·8) and 46 664 (62%) participants 
were men. 8168 (11%) individuals were from eastern Asia 
and 25 757 (34%) were from southern Asia; the ethnic 
origin of 1934 (3%) participants was black African and 
35 793 (48%) people were white. Participants in general 
population cohorts were younger, more likely to be men, 
more educated, and less active smokers than were 
individuals in high-risk population cohorts. The screened 
general population also had lower blood pressure, a higher 
eGFR, and a lower prevalence of albuminuria (table 1). No 
prominent sex diﬀ erences were recorded, except that men 
were more educated, more frequently employed, and more 
likely to be active smokers compared with women, both in 
general and in high-risk cohorts (appendix pp 1, 2).
Figure 2 shows the prevalence of chronic kidney disease 
in all 12 countries of low and middle income included in 
the ISN-KDDC study, and table 2 presents prevalence 
data adjusted by country, ethnic origin, and sex. In general 
population cohorts, the prevalence of chronic kidney 
disease was 14·3% (95% CI 14·0–14·5), with a prominent 
diﬀ erence by ethnic origin. Women had a higher 
prevalence of chronic kidney disease than did men. In 
screened general populations, the overall prevalence of 
decreased eGFR (<60 mL/min per 1·73 m²) was 9·8% 
(95% CI 9·6–10·0) and of albuminuria was 5·5% 
(5·4–5·7). However, in general population cohorts from 
China, Mongolia, India, Moldova, and Bolivia, the 
prevalence of albuminuria was higher than the prevalence 
of decreased eGFR. In high-risk populations, the overall 
prevalence of chronic kidney disease was 36·1% (95% CI 
34·7–37·6), with albuminuria having a greater eﬀ ect than 
in general populations, with a prevalence of 32·6% 
(31·2–34·0); the prevalence of decreased eGFR was 8·3% 
(7·5–9·1; table 2). The overall prevalence of chronic 
kidney disease in high-risk cohorts was greater in men 
than in women. According to the KDIGO classiﬁ cation, 
in the general population, fewer than 1% of individuals 
had severely increased albuminuria (category A3), and 
among those deﬁ ned as having albuminuria 
(categories A2 and A3), one in ﬁ ve participants had 
decreased eGFR (ﬁ gure 3A). However, in high-risk 
populations, severely increased albuminuria (category A3) 
was detected in 3% of patients, and among those with 
increased albuminuria (categories A2 and A3) every 
seventh patient had decreased eGFR (ﬁ gure 3B). The 
appendix (pp 4–9) shows the prevalence of chronic kidney 
disease in general population cohorts by world subregion.
Awareness of chronic kidney disease was very 
low in both the general and high-risk cohorts: 
409 (6%) of 6631 individuals in general populations and 
Figure 2: Prevalence of chronic kidney disease, by country
Data are prevalence (95% CI).
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150 (10%) of 1524 participants from high-risk populations 
were aware of their condition (table 1). A more detailed 
map of awareness about chronic kidney disease by eGFR 
and albuminuria categories (ﬁ gure 4) shows that some 
people with severe chronic kidney disease had very low 
awareness. In the general population, of 2783 individuals 
with albuminuria stages A2 and A3, 239 (9%) were aware 
they had chronic kidney disease, and of 905 with eGFR 
less than 45 mL/min per 1·73 m² (categories G3b, G4, 
and G5), 70 (8%) were aware of their condition. 
Corresponding awareness for high-risk populations was 
10% (139/1376) and 18% (28/156), respectively. Of 
patients who were aware of their chronic kidney disease, 
170 (42%) of 409 in general populations and 72 (48%) of 
150 in high-risk populations were reported as having any 
treatment for the condition. 
Participants (n) Men (%) Age (years) Prevalence (95% CI)
eGFR <60 mL/min per 
1·73 m2
ACR >30 mg/g Chronic kidney disease
General population cohorts
Eastern Asia .. .. .. .. .. ..
China 7340 25·9% 53·4 (10·2) 13·0% (12·2–13·8) 19·6% (18·7–20·5) 29·9% (28·9–31·0)
Mongolia 832 22·8% 41·1 (13·6) 9·6% (7·7–11·9) 11·3% (9·3–13·7) 18·0% (15·5–20·8)
Southern Asia .. .. .. .. .. ..
India 3196 42·9% 50·1 (13·4) 2·5% (2·0–3·1) 15·4% (14·1–16·7) 16·8% (15·5–18·1)
Nepal 21 066 38·6% 40·8 (15·6) 16·2% (15·7–16·7) 5·8% (5·5–6·2) 20·1% (19·6–20·6)
Middle East .. .. .. .. .. ..
Iran 31 615 98·4% 43·8 (11·3) 5·8% (5·5–6·0) 0·6% (0·5–0·7) 6·3% (6·1–6·6)
Africa .. .. .. .. .. ..
Nigeria 1912 36·6% 44·3 (13·2) 20·7% (18·9–22·6) 3·9% (3·1–4·9) 23·0% (21·2–25·0)
Eastern Europe .. .. .. .. .. ..
Moldova 1403 29·4% 50·7 (14·3) 11·2% (9·6–13·0) 17·1% (15·2–19·2) 25·5% (23·3–27·9)
Latin America .. .. .. .. .. ..
Bolivia 3410 36·1% 41·6 (13·7) 1·7% (1·3–2·2) 4·5% (3·9–5·3) 5·5% (4·7–6·3)
Ethnic origin .. .. .. .. .. ..
Eastern Asian 8168 25·6% 52·1 (11·2) 12·6% (11·9–13·4) 18·8% (17·9–19·6) 28·7% (27·7–29·7)
Southern Asian 24 244 39·1% 42·0 (15·7) 14·4% (13·9–14·8) 7·1% (6·8–7·4) 19·7% (19·2–20·2)
Black African 1934 37·1% 44·3 (13·2) 20·5% (18·7–22·4) 4·0% (3·2–5·0) 23·0% (21·1–24·9)
White 33 022 95·5% 44·1 (11·5) 6·0% (5·8–6·3) 1·3% (1·2–1·4) 7·1% (6·9–7·4)
Other 3406 36·1% 41·6 (13·7) 1·7% (1·3–2·2) 4·5% (3·8–5·2) 5·5% (4·7–6·3)
Sex .. .. .. .. .. ..
Men 45 041 .. 44·2 (13·1) 7·3% (7·1–7·6) 3·0% (2·9–3·2) 9·7% (9·5–10·0)
Women 25 733 .. 44·1 (14·3) 14·2% (13·8–14·6) 9·9% (9·5–10·3) 22·2% (21·7–22·7)
Overall 70 774 63·6% 44·2 (13·5) 9·8% (9·6–10·0) 5·5% (5·4–5·7) 14·3% (14·0–14·5)
High-risk population cohorts
Southern Asia .. .. .. .. .. ..
Bangladesh 1511 43·3% 47·2 (15·9) 8·5% (7·1–10·0) 45·4% (42·9–48·0) 49·3% (46·8–51·9)
Middle East .. .. .. .. .. ..
Egypt 412 56·3% 39·1 (14·3) 7·5% (5·3–10·6) 29·6% (25·3–34·3) 32·3% (27·8–37·1)
Eastern Europe 2361 31·2% 53·2 (15·3) 8·3% (7·2–9·5) 24·9% (23·2–26·8) 28·3% (26·5–30·2)
Bosnia and Herzegovina 798 42·6% 57·0 (15·0) 14·9% (12·6–17·6) 39·1% (35·7–42·6) 45·9% (42·4–49·4)
Georgia 1563 25·3% 51·2 (15·0) 4·9% (3·9–6·1) 17·7% (15·9–19·7) 19·4% (17·5–21·5)
Ethnic origin .. .. .. .. .. ..
Southern Asian 1513 43·3% 47·2 (15·9) 8·5% (7·1–10·0) 45·3% (42·8–47·9) 49·2% (46·7–51·8)
White 2771 34·9% 51·1 (15·9) 8·2% (7·2–9·3) 25·7% (24·0–27·3) 28·9% (27·3–30·7)
Sex .. .. .. .. .. ..
Men 1623 .. 49·7 (16·7) 6·4% (5·3–7·7) 37·6% (35·3–40·1) 40·0% (37·7–42·5)
Women 2661 .. 49·7 (15·6) 9·4% (8·3–10·6 ) 29·5% (27·8–31·3) 33·7% (31·9–35·5)
Overall 4284 37·9% 49·7 (16·0) 8·3% (7·5–9·1) 32·6% (31·2–34·0) 36·1% (34·7–37·6)
Data are adjusted prevalence (95% CI) or mean (SD), unless otherwise stated. ACR=albumin-to-creatinine ratio approximate equivalent. eGFR=estimated glomerular ﬁ ltration rate.
Table 2: Prevalence of decreased eGFR, albuminuria, and chronic kidney disease, adjusted for country, ethnic origin, and sex
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Awareness of disorders representing major risk 
factors for chronic kidney disease was higher than for 
chronic kidney disease (table 1). In the general 
population, 7151 (56%) of 12 751 individuals knew they 
had hypertension, but only half (3485/7151 [49%]) 
were taking antihypertensive drugs. Awareness of 
hypertension was higher in high-risk populations 
(2002/2710 [74%]), but even among this group, almost 
one in four individuals did not know about elevated 
blood pressure and 1815 (91%) of 2002 were prescribed 
appropriate treatment (appendix pp 1, 2).  With respect to 
diabetes, 2157 (69%) of 3130 individuals in the general 
population and 588 (80%) of 738 in the high-risk 
population were aware of existing disease. Only 
1544 (72%) of 2157 patients in general cohorts and 
514 (87%) of 588 in high-risk populations who 
were aware of existing diabetes reported taking anti-
diabetes drugs.
Several risk factors were associated with chronic kidney 
disease in the general population cohorts, at overall study 
population level or adjusted by cohort, and adjusted for 
cohort, age, and sex (table 3). In multiple logistic 
regression analyses, hypertension, diabetes, obesity, and 
high cholesterol were all associated independently with 
chronic kidney disease (overall, and for almost all 
regions). Overall, the odds of detecting chronic kidney 
disease were increased signiﬁ cantly in individuals with 
hypertension (adjusted odds ratio 1·68, 95% CI 
1·60–1·76), diabetes (1·75, 1·62–1·89), obesity (1·07, 
1·01–1·14), and high serum cholesterol (1·22, 1·13–1·31). 
Data for the prevalence of risk factors for chronic kidney 
disease in individuals in the general population cohort 
who have chronic kidney disease are presented in the 
appendix (p 3).
In the general population cohort (n=67 009), 
50 033 (75%) individuals were at low risk, 10 587 (16%) 
were at medium risk, and 6389 (10%) were at high risk 
of developing cardiovascular disease in the next 
10 years. In the high-risk population cohort (n=4250), 
2084 (49%) participants were at low risk, 770 (18%) were 
at medium risk, and 1396 (33%) were at high risk. 
Figure 5 shows the proportion of the population at 
high risk of developing cardiovascular disease in the 
next 10 years, by eGFR and albuminuria categories. 
Individuals in a higher category of albuminuria (A2 
and A3) or decreased eGFR (G3a to G5) had a striking 
increase in 10-year risk, and the risk was even higher 
for individuals with both markers of kidney damage 
and dysfunction.
Figure 3: Prevalence of chronic kidney disease by eGFR and albuminuria 
categories, overall and stratiﬁ ed by sex
Data are %. Chronic kidney disease-related risk deﬁ ned as: green, low risk 
(if no other markers of kidney disease, no chronic kidney disease); yellow, 
moderately increased risk; orange, high risk; red, very high risk.3 eGFR was 
calculated with the CKD-EPI equation:21 G1, normal or high 
(≥90 mL/min per 1·73 m²); G2, mildly decreased (60–89  mL/min per 1·73 m²); 
G3a, mildly to moderately decreased (45–59 mL/min per 1·73 m²); G3b, 
moderately to severely decreased (30–44 mL/min per 1·73 m²); G4, severely 
decreased (15–29 mL/min per 1·73 m²) and G5, kidney failure 
(<15 mL/min per 1·73 m²). Albuminuria categories were deﬁ ned as ACR 
approximate equivalent: A1, normal to mildly increased (ACR <30 mg/g); A2, 
moderately increased (ACR ≥30 mg/g to <300 mg/g); A3, severely increased 
(ACR ≥300 mg/g). ACR=albumin-to-creatinine ratio. eGFR=estimated 
glomerular ﬁ ltration rate. 
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Discussion
The ﬁ ndings of the ISN-KDDC study are estimates for 
the prevalence of chronic kidney disease in populations 
of 12 low-income and middle-income countries in 
six regions of the world belonging to the ISN-KHDC and 
aﬃ  liated programmes. In the general population, the 
overall prevalence of chronic kidney disease was 14·3%, 
ranging from 5·5% in Bolivia to 29·9% in China. The 
mean prevalence of chronic kidney disease across all 
12 countries was similar to the ﬁ gure of 10–13% recorded 
by high-quality screening programmes in high-income 
countries.6,29
The speciﬁ c features of the studied population could 
account for the variability in prevalence of chronic kidney 
disease we noted in the general cohorts. One of the 
lowest values for prevalence of chronic kidney disease 
was recorded in predominantly healthy, young (mean age 
44 years), male taxi drivers in Iran,19 whereas the highest 
prevalence was detected in China, where participants 
were older (mean age 53 years), 30% had elevated blood 
pressure, and 6% had diabetes.15 Moreover, we recorded 
diﬀ erences in ethnic origin, with a much lower 
prevalence of chronic kidney disease in white populations 
compared with people from Asian and black African 
backgrounds, which could be related to the known eﬀ ect 
of ethnic origin on development of chronic kidney 
disease.30 Nevertheless, it should be taken into account 
that the main objective of the ISN KHDC-based screening 
programmes,14 established in 2005, was not to estimate 
the true prevalence of chronic kidney disease by repeat 
testing, as recommended by KDIGO guidelines 
published in 2012,3 but to identify individuals at risk of or 
with kidney disease and to include them in follow-up 
programmes aimed at limiting morbidity and mortality 
related to complications of renal and cardiovascular 
disease in countries of low and middle income. Moreover, 
these ISN programmes provided an integrated view on 
the assessment of non-communicable diseases, which 
included detection of kidney abnormalities in the context 
of a wide range of risk factors and chronic diseases.
Screening for chronic kidney disease in high-risk 
populations (people with diabetes or hypertension, or 
who are older than 60 years) is recommended by the 
latest KDIGO guidelines3 and most,31 but not all,32 cost-
eﬀ ectiveness studies. Conversely, screening for chronic 
kidney disease in the general population is not 
recommended by the US Preventive Task Force33 because 
of the absence of high-quality data that can forecast its 
eﬀ ectiveness in preventing complications. However, 
evidence shows that screening for chronic kidney disease 
Figure 4: Awareness of chronic kidney disease by eGFR and albuminuria 
categories, overall and stratiﬁ ed by sex
Data are %. Chronic kidney disease-related risk deﬁ ned as: green, low risk 
(if no other markers of kidney disease, no chronic kidney disease); 
yellow, moderately increased risk; orange, high risk; red, very high risk.3 
eGFR was calculated with the CKD-EPI equation:21 G1, normal or high 
(≥90 mL/min per 1·73 m²); G2, mildly decreased (60–89  mL/min per 1·73 m²); 
G3a, mildly to moderately decreased (45–59 mL/min per 1·73 m²); G3b, 
moderately to severely decreased (30–44 mL/min per 1·73 m²); G4, severely 
decreased (15–29 mL/min per 1·73 m²) and G5, kidney failure 
(<15 mL/min per 1·73 m²). Albuminuria categories were deﬁ ned as ACR 
approximate equivalent: A1, normal to mildly increased (ACR <30 mg/g); 
A2, moderately increased (ACR ≥30 mg/g to <300 mg/g); A3, severely increased 
(ACR ≥300 mg/g). ACR=albumin-to-creatinine ratio. eGFR=estimated glomerular 
ﬁ ltration rate. NA=no data available.
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in the general population is plausible even for healthy 
individuals older than 50 years when done once every 
10 years, which strikingly increases its cost-eﬀ ectiveness.34 
Almost all recommendations—both for and against 
screening for chronic kidney disease—are based on data 
from the developed world.
Although our study is not a cost-eﬀ ectiveness analysis, 
our data provide important insights into the usefulness of 
screening for chronic kidney disease and its risk factors, 
both in general population and high-risk cohorts in 
countries of low and middle income. In particular, 
we found that in screened individuals, awareness of 
chronic kidney disease, hypertension, or diabetes was 
low: more than 90% of individuals did not know they had 
chronic kidney disease, almost every second screened 
patient did not know about his or her hypertension, and 
close to every third screened individual was unaware of 
his or her diabetes. These ﬁ ndings parallel those of a 
large-scale screening programme in Brazil,35 where more 
than four-ﬁ fths of individuals with detected proteinuria 
were unaware of chronic kidney disease and roughly a 
quarter of the screened population with recorded high 
blood pressure did not know they had hypertension. In 
India,36 only 2% of screened participants diagnosed with 
chronic kidney disease had a self-reported history of 
kidney disease, and in China,29 a third of the rural and 
two-thirds of the urban population were unaware of their 
diabetes.
Our estimated awareness of chronic kidney disease 
(6% and 10%, for general and high-risk population 
cohorts, respectively) in low-income and middle-income 
countries seems comparable with data from developed 
countries. In US Kidney Early Evaluation Program 
(KEEP) screening programmes, the prevalence of 
patients aware of their existing chronic kidney disease 
was 7%37 or 9%.38 However, in a smaller cohort of KEEP 
participants with presumed chronic kidney disease, 
based on one measurement of renal function, awareness 
of chronic kidney disease was higher, up to 23%.39
Furthermore, our study highlights that, in general 
populations, almost half of patients with high blood 
pressure did not take antihypertensive drugs and a third 
of people known to have diabetes did not receive 
antidiabetes drugs, which indicates that, in countries of 
low and middle income, a substantial number of patients 
have no access to appropriate treatment, even though 
both diabetes and hypertension are major risk factors for 
development and progression of chronic kidney disease, 
Hypertension Diabetes Obesity Hypercholesterolaemia
Odds ratio (95% CI) p Odds ratio (95% CI) p Odds ratio (95% CI) p Odds ratio (95% CI) p
Overall (univariable 
logistic regression)*
2·88 (2·76–3·01) <0·001 2·43 (2·25–2·62) <0·001 1·32 (1·25–1·39) <0·001 1·49 (1·39–1·59) <0·001
World subregions† ·· ·· ·· ·· ·· ·· ·· ··
Eastern Asia 
(China, Mongolia)
1·25 (1·09–1·43) 0·001 1·81 (1·38–2·38) <0·001 1·62 (1·23–2·12) <0·001 2·06 (1·36–3·09) <0·001
Southern Asia 
(India, Nepal)
2·58 (2·42–2·75) <0·001 3·14 (2·87–3·44) <0·001 1·67 (1·54–1·81) <0·001 2·21 (1·89–2·59) <0·001
Middle East (Iran) 2·44 (2·17–2·75) <0·001 NA .. 1·18 (1·03–1·35) 0·019 1·91 (1·71–2·13) <0·001
Africa (Nigeria) 1·43 (1·15–1·77) 0·001 1·71 (1·13–2·55) 0·009 1·24 (0·94–1·63) 0·116 1·93 (1·49–2·48) <0·001
Eastern Europe 
(Moldova)
1·93 (1·49–2·49) <0·001 2·74 (1·97–3·78) <0·001 1·40 (1·09–1·80) 0·009 2·49 (1·83–3·39) <0·001
Latin America 
(Bolivia)
6·17 (4·56–8·38) <0·001 8·22 (4·89–13·42) <0·001 1·77 (1·28–2·43) <0·001 NA ..
Overall (multiple 
logistic regression)‡
1·68 (1·60–1·76) <0·001 1·75 (1·62–1·89) <0·001 1·07 (1·01–1·14) 0·019 1·22 (1·13–1·31) <0·001
World subregions§ ·· ·· ·· ·· ·· ·· ·· ··
Eastern Asia 
(China, Mongolia)
1·01 (0·88–1·15) 0·940 1·44 (1·09–1·91) 0·010 1·58 (1·20–2·08) 0·001 1·90 (1·25–2·87) 0·002
Southern Asia 
(India, Nepal)
1·57 (1·47–1·69) <0·001 2·25 (2·04–2·48) <0·001 1·43 (1·31–1·55) <0·001 1·64 (1·38–1·94) <0·001
Middle East (Iran) 1·73 (1·54–1·95) <0·001 NA .. 1·21 (1·05–1·38) 0·007 1·73 (1·54–1·93) <0·001
Africa (Nigeria) 1·01 (0·81–1·27) 0·909 1·29 (0·85–1·95) 0·217 1·03 (0·78–1·36) 0·837 1·29 (0·98–1·68) 0·060
Eastern Europe 
(Moldova)
1·07 (0·82–1·40) 0·604 2·13 (1·52–2·97) <0·001 1·13 (0·87–1·46) 0·374 1·98 (1·42–2·74) <0·001
Latin America 
(Bolivia)
3·93 (2·89–5·37) <0·001 4·58 (2·69–7·58) <0·001 1·25 (0·89–1·72) 0·186 NA ..
Odds ratios are for prediction of chronic kidney disease. NA=no data available in the subset for the corresponding predictor. *Univariable logistic regression included risk 
factor only. †Multiple logistic regression included risk factor, cohort, and risk factor:cohort interaction. ‡Multiple logistic regression included risk factor, age, and sex. 
§Multiple logistic regression included risk factor, age, sex, cohort, and risk factor:cohort interaction.
Table 3: Risk factors associated with chronic kidney disease in general population cohorts 
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and for complications and mortality from chronic kidney 
disease.40,41 Indeed, our analysis conﬁ rmed the increased 
odds of detecting chronic kidney disease in patients with 
elevated blood pressure, diabetes, obesity, and high 
amounts of cholesterol in serum. In a subset of patients, 
we also detected a high prevalence of smoking, in either 
general (22%) or high-risk (34%) population cohorts, 
which is known as one of the risk factors for development 
of chronic kidney disease, not only during adult life42 but 
also via epigenetic modiﬁ cation and mitochondrial 
dysfunction during fetal programming.43
According to the latest nephrology44 and cardiology40,41 
guidelines, all people with chronic kidney disease should 
be judged at high risk of complications from chronic 
kidney disease. However, no markers of chronic kidney 
disease (eg, decreased eGFR and increased albuminuria) 
are included in risk scores for cardiovascular disease, 
including the Framingham risk score—the non-laboratory-
based version of which26 we used to calculate the 10-year 
risk for developing cardiovascular disease in our study. 
Nevertheless, we reported an incremental increase in 
cumulative eﬀ ect of reduced eGFR and increased 
albuminuria on the Framingham risk score, but the risk 
was substantially underestimated for most patients with 
chronic kidney disease. 35% of individuals in eGFR 
category 3B, and 20% and 31% of those in albuminuria 
category A2 and A3, respectively, would have been 
recognised by the Framingham risk score as being at high 
risk of cardiovascular disease, whereas all these patients 
are classiﬁ ed as high risk by KDIGO guidelines.3 These 
ﬁ ndings suggest that timely recognition of chronic kidney 
disease could provide additional key information to 
appropriately estimate risk of cardiovascular disease in 
screened individuals in general populations in low-income 
and middle-income countries.
Our study has several limitations. First, individuals 
were screened based on convenience sampling with 
active referral from advertisements, or on speciﬁ c 
geographical areas; thus, participants were not randomly 
selected from the whole population. Therefore, we 
cannot infer per country representativeness of renal 
abnormalities. This selection bias could have led us to 
overestimate the prevalence of chronic kidney disease in 
some regions, because we assessed people who 
volunteered to be tested.45 Such bias has been proven in a 
US study comparing random selection in the NHANES 
study with active referral in the KEEP study,37 in which 
the prevalence of chronic kidney disease was 13·1% and 
28·7%, respectively. Similarly, in our screening 
programme in India, the prevalence of chronic kidney 
disease was 16·8%, but in another study in which 
random multistage cluster sampling was used,36 
prevalence was only 7·5%. Second, laboratory methods 
for measurement of creatinine were not standardised, 
which could introduce bias both for comparison of the 
prevalence of low eGFR between study sites and for 
adequate calculation of eGFR with the CKD-EPI 
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Figure 5: Proportion of population at high risk of developing cardiovascular disease in the next 10 years by 
eGFR and albuminuria categories, overall and stratiﬁ ed by sex
Risk calculated according to the simpler risk prediction Framingham risk score equation based on non-laboratory 
predictors (sex, age, diabetes, and smoking status, treated or untreated hypertension, and body-mass index).26 
High risk deﬁ ned as a probability greater than 20%. eGFR was calculated with the CKD-EPI equation:21 G1, normal or 
high (≥90 mL/min per 1·73 m²); G2, mildly decreased (60–89  mL/min per 1·73 m²); G3a, mildly to moderately 
decreased (45–59 mL/min per 1·73 m²); G3b, moderately to severely decreased (30–44 mL/min per 1·73 m²); G4, 
severely decreased (15–29 mL/min per 1·73 m²) and G5, kidney failure (<15 mL/min per 1·73 m²). Albuminuria 
categories were deﬁ ned as ACR approximate equivalent: A1, normal to mildly increased (ACR <30 mg/g); A2, 
moderately increased (ACR ≥30 mg/g to <300 mg/g); A3, severely increased (ACR ≥300 mg/g). 
ACR=albumin-to-creatinine ratio. eGFR=estimated glomerular ﬁ ltration rate.
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formula,21 which assumes creatinine standardisation 
(with a costly reference standard that is unaﬀ ordable for 
most countries of low and middle income). However, 
in every country of low and middle income, creatinine 
measurement was calibrated according to manufacturer 
guidelines, which should have prevented major bias. 
Third, in most individuals, determinants of chronic 
kidney disease were based on one measurement of 
creatinine in serum and albuminuria, which could have 
contributed to overdiagnosis of chronic kidney disease in 
some screened individuals with transient changes in 
these variables. This approach is widespread in published 
literature on the epidemiology of chronic kidney disease: 
urinalysis and measurement of serum creatinine to 
calculate eGFR was done only once in studies of the 
prevalence of chronic kidney disease in the general 
population of high-income European countries46–48 and 
the USA39,49 and in nationally representative screening for 
chronic kidney disease in China.29 Although at the 
population level, one-time measurement of markers of 
chronic kidney disease is common and could be 
acceptable for estimation of prevalence, on the individual 
patient level, obligatory conﬁ rmation of initial 
abnormalities should be done. To better discriminate the 
management strategy at population and individual levels, 
ﬁ ndings obtained during screening—in which one 
calculation for eGFR and one evaluation of urinalysis 
was done—could be described more precisely as the 
prevalence of a positive screening test for chronic kidney 
disease, to which we refer in our analysis, while using 
the generally accepted term chronic kidney disease. 
Although there is a risk of false-positive results with this 
approach,6 the main screening goal, particularly in 
countries of low and middle income, is to avoid false-
negative ﬁ ndings. Therefore, in case of a positive result 
after initial detection, conﬁ rmatory assessment should 
be set up before any intervention treatment is started or 
the patient is referred to a specialist. Finally, eGFR was 
calculated with the CKD-EPI equation,21 which was 
developed for the US population, and although this 
formula includes a coeﬃ  cient for ethnic origin, it could 
indicate eGFR imprecisely in multiethnic cohorts. 
Several diﬀ erent coeﬃ  cients have been proposed for 
Asian and black populations,44,50,51 but currently they are 
neither widely recommended nor validated.52 Moreover, 
in Chinese populations, the CKD-EPI two-level race 
equation was proven better than the Modiﬁ cation of Diet 
in Renal Disease (MDRD) study equation and the CKD-
EPI four-level race equation.53 Thus, in our multiethnic 
cohort, we used the recommended3 two-level race CKD-
EPI equation.
Although formal comparison across diﬀ erent 
populations is prevented by variable sampling strategies, 
our use of identical cutoﬀ s for clinical and laboratory 
variables, the same screening protocol, one web-based 
database for data entry and centralised data monitoring 
in most cases, and inclusion of both urban and rural 
populations in screening and the programmes makes 
our analysis a unique opportunity to study the 
prevalence of chronic kidney disease and other non-
communicable diseases in countries of low and middle 
income. In conclusion, decreased eGFR and increased 
albuminuria—and the resulting prevalence of chronic 
kidney disease—are common in the general populations 
of countries of low and middle income. Our results not 
only suggest the feasibility of screening in poor-resource 
settings but also underline that, without local screening 
programmes, most individuals in these regions remain 
unaware of existing chronic kidney disease and its risk 
factors. This sparse knowledge precludes any 
appropriate prevention, follow-up, and treatment 
programmes for patients in need. In view of the major 
eﬀ ect renal abnormalities have on cardiovascular 
disease, such screening programmes—complemented 
by sustainable management of patients who screen 
positive—should be implemented urgently with 
adjustments for local settings, along with generally 
strengthening the health-care workforce and making 
cheap drugs accessible to local populations. Prospective 
studies are warranted to quantify the potential beneﬁ ts 
of this type of prevention strategy in countries of low 
and middle income.
Contributors
BE-I, GR, NP, and BB developed the idea for the study. NI, RFB, MA-H, 
HZ, LZ, ZG, IT, GA, MM-M, MG, IC, AT, SKS, PK, SU, and IU were 
principal investigators, responsible for the screening programmes in 
their respective countries, and participated in data collection. BE-I, SC, 
and AR contributed to setting up the ISN-KDDC database. BE-I and SC 
assessed the quality of data entry and did analyses. BE-I, NP, BB, AP, 
and GR contributed to data analyses and interpretation. BE-I wrote the 
ﬁ rst draft, and together with NP and BB, the ﬁ nal version of the report. 
All authors approved the ﬁ nal manuscript.
Declaration of interests
We declare no competing interests.
Acknowledgments
Data collection through the International Society of Nephrology (ISN) 
Kidney Disease Data Center (KDDC) and analyses were funded partly by 
a grant from the ISN. All screening programmes, except that of the 
TANKER Foundation (Chennai, India) and in Iran, were funded partly 
by a dedicated grant from the ISN Research and Prevention Committee. 
We thank the doctors, nurses, local students, volunteers, and 
organisations involved in the country screening programmes for their 
active participation and support, which made collection of clinical data 
in the ISN-KDDC study database possible. The ISN-KDDC study 
organisation is presented in the appendix (pp 10–12). We also thank 
Kerstin Mierke for editorial assistance during preparation of the report.
References
1 GBD 2013 Mortality and Causes of Death Collaborators. Global, 
regional, and national age–sex speciﬁ c all-cause and cause-speciﬁ c 
mortality for 240 causes of death, 1990–2013: a systematic analysis 
for the Global Burden of Disease Study 2013. Lancet 2015; 
385: 117–71.
2 Global Burden of Disease Study 2013 Collaborators. Global, 
regional, and national incidence, prevalence, and years lived with 
disability for 301 acute and chronic diseases and injuries in 
188 countries, 1990–2013: a systematic analysis for the Global 
Burden of Disease Study 2013. Lancet 2015; 386: 743–800.
3 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work 
Group. KDIGO 2012 clinical practice guideline for the evaluation 
and management of chronic kidney disease. Kidney Int Suppl 2013; 
3: 1–150.
Articles
e318 www.thelancet.com/lancetgh   Vol 4   May 2016
4 White SL, Chadban SJ, Jan S, Chapman JR, Cass A. How can we 
achieve global equity in provision of renal replacement therapy? 
Bull World Health Organ 2008; 86: 229–37.
5 Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of 
chronic kidney disease to the global burden of major 
noncommunicable diseases. Kidney Int 2011; 80: 1258–70.
6 Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of 
chronic kidney disease and decreased kidney function in the adult 
US population: Third National Health and Nutrition Examination 
Survey. Am J Kidney Dis 2003; 41: 1–12.
7 Hallan SI, Coresh J, Astor BC, et al. International comparison of 
the relationship of chronic kidney disease prevalence and ESRD 
risk. J Am Soc Nephrol 2006; 17: 2275–84.
8 Hillege HL, Janssen WM, Bak AA, et al. Microalbuminuria is 
common, also in a nondiabetic, nonhypertensive population, 
and an independent indicator of cardiovascular risk factors and 
cardiovascular morbidity. J Intern Med 2001; 249: 519–26.
9 Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney 
damage in Australian adults: the AusDiab kidney study. 
J Am Soc Nephrol 2003; 14 (7 suppl 2): S131–38.
10 Stanifer JW, Jing B, Tolan S, et al. The epidemiology of chronic 
kidney disease in sub-Saharan Africa: a systematic review and 
meta-analysis. Lancet Glob Health 2014; 2: e174–81.
11 Rosenberg AZ, Naicker S, Winkler CA, Kopp JB. HIV-associated 
nephropathies: epidemiology, pathology, mechanisms and 
treatment. Nat Rev Nephrol 2015; 11: 150–60.
12 Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: 
global dimension and perspectives. Lancet 2013; 382: 260–72.
13 Correa-Rotter R, Wesseling C, Johnson RJ. CKD of unknown origin 
in Central America: the case for a Mesoamerican nephropathy. 
Am J Kidney Dis 2014; 63: 506–20.
14 International Society of Nephrology. Clinical research program. 
2016. http://www.theisn.org/programs/clinical-research-program 
(accessed Nov 11, 2015).
15 Sharma SK, Zou H, Togtokh A, et al. Burden of CKD, proteinuria, 
and cardiovascular risk among Chinese, Mongolian, and Nepalese 
participants in the International Society of Nephrology screening 
programs. Am J Kidney Dis 2010; 56: 915–27.
16 Gallieni M, Ene-Iordache B, Aiello A, et al. Hypertension and 
kidney function in an adult population of West Bengal, India: 
Role of body weight, waist circumference, proteinuria and rural 
area living. Nephrology (Carlton) 2013; 18: 798–807.
17 Codreanu I, Sali V, Gaibu S, et al. Prevalence of hypertension and 
diabetes and coexistence of chronic kidney disease and 
cardiovascular risk in the population of the Republic of Moldova. 
Int J Hypertens 2012; 2012: 951734.
18 Cravedi P, Sharma SK, Bravo RF, et al. Preventing renal and 
cardiovascular risk by renal function assessment: insights from a 
cross-sectional study in low-income countries and the USA. 
BMJ Open 2012; 2: e001357.
19 Mahdavi-Mazdeh M, Saeed Hashemi Nazri S, Hajghasemi E, 
Nozari B, Zinat Nadia H, Mahdavi A. Screening for decreased 
renal function in taxi drivers in Tehran, Iran. Ren Fail 2010; 
32: 62–68.
20 Gouda Z, Mashaal G, Bello AK, et al. Egypt Information, 
Prevention, and Treatment of Chronic Kidney Disease 
(EGIPT-CKD) programme: prevalence and risk factors for 
microalbuminuria among the relatives of patients with CKD in 
Egypt. Saudi J Kidney Dis Transpl 2011; 22: 1055–63.
21 Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate 
glomerular ﬁ ltration rate. Ann Intern Med 2009; 150: 604–12.
22 Wen CP, Matsushita K, Coresh J, et al. Relative risks of chronic 
kidney disease for mortality and end-stage renal disease across 
races are similar. Kidney Int 2014; 86: 819–27.
23 Chobanian AV, Bakris GL, Black HR, et al, and the National High 
Blood Pressure Education Program Coordinating Committee. 
The Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure: the 
JNC 7 report. JAMA 2003; 289: 2560–72.
24 WHO. Obesity: preventing and managing the global epidemic. 
Geneva: World Health Organization, 2000.
25 WHO Expert Consultation. Appropriate body-mass index for Asian 
populations and its implications for policy and intervention 
strategies. Lancet 2004; 363: 157–63.
26 D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General 
cardiovascular risk proﬁ le for use in primary care: the Framingham 
Heart Study. Circulation 2008; 117: 743–53.
27 Cooney MT, Dudina A, D’Agostino R, Graham IM. Cardiovascular 
risk-estimation systems in primary prevention: do they diﬀ er? 
Do they make a diﬀ erence? Can we see the future? Circulation 2010; 
122: 300–10.
28 Selvarajah S, Kaur G, Haniﬀ  J, et al. Comparison of the 
Framingham Risk Score, SCORE and WHO/ISH cardiovascular 
risk prediction models in an Asian population. Int J Cardiol 2014; 
176: 211–18.
29 Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney 
disease in China: a cross-sectional survey. Lancet 2012; 
379: 815–22.
30 Freedman BI, Divers J, Palmer ND. Population ancestry and genetic 
risk for diabetes and kidney, cardiovascular, and bone disease: 
modiﬁ able environmental factors may produce the cures. 
Am J Kidney Dis 2013; 62: 1165–75.
31 Vassalotti JA, Fox CH, Becker BN. Risk factors and screening for 
chronic kidney disease. Adv Chronic Kidney Dis 2010; 17: 237–45.
32 Manns B, Hemmelgarn B, Tonelli M, et al. Population based 
screening for chronic kidney disease: cost eﬀ ectiveness study. 
BMJ 2010; 341: c5869.
33 Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, 
and treatment of chronic kidney disease stages 1 to 3: a systematic 
review for the U S Preventive Services Task Force and for an 
American College of Physicians Clinical Practice Guideline. 
Ann Intern Med 2012; 156: 570–81.
34 Kessler R, Keusch G, Szucs TD, et al. Health economic modelling 
of the cost-eﬀ ectiveness of microalbuminuria screening in 
Switzerland. Swiss Med Wkly 2012; 142: w13508.
35 de Lima AO, Kesrouani S, Gomes RA, Cruz J, 
Mastroianni-Kirsztajn G. Population screening for chronic kidney 
disease: a survey involving 38,721 Brazilians. Nephrol Dial Transplant 
2012; 27 (suppl 3): iii135–38.
36 Anand S, Shivashankar R, Ali MK, et al. Prevalence of chronic 
kidney disease in two major Indian cities and projections for 
associated cardiovascular disease. Kidney Int 2015; 88: 178–85.
37 Vassalotti JA, Li S, Chen SC, Collins AJ. Screening populations at 
increased risk of CKD: the Kidney Early Evaluation Program (KEEP) 
and the public health problem. Am J Kidney Dis 2009; 
53 (3 suppl 3): S107–14.
38 Whaley-Connell A, Shlipak MG, Inker LA, et al. Awareness of 
kidney disease and relationship to end-stage renal disease and 
mortality. Am J Med 2012; 125: 661–69.
39 Shah A, Fried LF, Chen SC, et al. Associations between access to 
care and awareness of CKD. Am J Kidney Dis 2012; 
59 (3 suppl 2): S16–23.
40 Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a 
risk factor for development of cardiovascular disease: a statement 
from the American Heart Association Councils on Kidney in 
Cardiovascular Disease, High Blood Pressure Research, Clinical 
Cardiology, and Epidemiology and Prevention. Circulation 2003; 
108: 2154–69.
41 Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on 
cardiovascular disease prevention in clinical practice: executive 
summary—Fourth Joint Task Force of the European Society of 
Cardiology and Other Societies on Cardiovascular Disease 
Prevention in Clinical Practice (constituted by representatives of 
nine societies and by invited experts). Eur Heart J 2007; 
28: 2375–414.
42 Orth SR. Smoking and the kidney. J Am Soc Nephrol 2002; 
13: 1663–72.
43 Stangenberg S, Chen H, Wong MG, Pollock CA, Saad S. 
Fetal programming of chronic kidney disease: the role of maternal 
smoking, mitochondrial dysfunction, and epigenetic modﬁ ﬁ cation. 
Am J Physiol Renal Physiol 2015; 308: F1189–96.
44 Stevens LA, Claybon MA, Schmid CH, et al. Evaluation of the 
Chronic Kidney Disease Epidemiology Collaboration equation for 
estimating the glomerular ﬁ ltration rate in multiple ethnicities. 
Kidney Int 2011; 79: 555–62.
45 Jaar BG, Khatib R, Plantinga L, Boulware LE, Powe NR. Principles 
of screening for chronic kidney disease. Clin J Am Soc Nephrol 2008; 
3: 601–09.
Articles
www.thelancet.com/lancetgh   Vol 4   May 2016 e319
46 Brück K, Jager KJ, Dounousi E, et al. Methodology used in studies 
reporting chronic kidney disease prevalence: a systematic literature 
review. Nephrol Dial Transplant 2015; 30 (suppl 4): iv6–16.
47 Brück K, Stel VS, Gambaro G, et al, and on behalf of the European 
CKD Burden Consortium. CKD prevalence varies across the 
European general population. J Am Soc Nephrol 2015; published 
online Dec 23. DOI:10.1681/ASN.2015050542.
48 Aitken GR, Roderick PJ, Fraser S, et al. Change in prevalence of 
chronic kidney disease in England over time: comparison of 
nationally representative cross-sectional surveys from 2003 to 2010. 
BMJ Open 2014; 4: e005480.
49 United States Renal Data System. CKD analytic methods. 
In: 2015 annual data report: vol 1, chronic kidney disease (CKD) in 
the United States. Bethesda: National Institutes of Health, National 
Institute of Diabetes and Digestive and Kidney Diseases, 2015.
50 Teo BW, Xu H, Wang D, et al. GFR estimating equations in a 
multiethnic Asian population. Am J Kidney Dis 2011; 58: 56–63.
51 Jessani S, Levey AS, Bux R, et al. Estimation of GFR in South 
Asians: a study from the general population in Pakistan. 
Am J Kidney Dis 2014; 63: 49–58.
52 Delanaye P, Mariat C. The applicability of eGFR equations to 
diﬀ erent populations. Nat Rev Nephrol 2013; 9: 513–22.
53 Kong X, Ma Y, Chen J, et al. Evaluation of the Chronic Kidney 
Disease Epidemiology Collaboration equation for estimating 
glomerular ﬁ ltration rate in the Chinese population. 
Nephrol Dial Transplant 2013; 28: 641–51.
